
Opinion|Videos|May 15, 2024
In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs
Selina McGee, OD, FAAO, evaluates the cost and efficacy of in-office procedures like microblepharoexfoliation, the potential clinical and economic costs associated with delaying access to the FDA-approved treatment through prior authorization or mandating prior use of traditional over-the-counter therapies like tea tree oil and lid wipes, and considers impact on patient adherence.
Advertisement
Episodes in this series

Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
Cancer survival fell and deaths rose during first two years of COVID-19
3
TrumpRx launches; some experts question its long-term value
4
PBM reform. It has finally happened
5






















